UNCY Unicycive Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1766140 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-8.4%
TTM EPS YoY53.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-80.4%
ROA-60.1%
ROIC (approx.)-1,005.6%
Asset turnover—
Leverage & solvency
Liabilities / assets24.8%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $9.12M | $20.01M |
| SG&A expense | $20.40M | $12.10M |
| Operating income | -$29.52M | -$32.12M |
| Interest expense | $71,000 | $71,000 |
| Net income | -$26.55M | -$36.73M |
| EBITDA | -$29.48M | -$32.09M |
| EPS (basic) | -1.67 | -5.65 |
| EPS (diluted) | -1.67 | -5.65 |
| Weighted avg. shares (diluted) | 15.89M | 6.70M |
| Balance sheet | ||
| Cash & equivalents | $29.20M | $26.14M |
| Short-term investments | $12.07M | — |
| Current assets | $48.96M | $30.95M |
| PP&E, net | $66,000 | $75,000 |
| Total assets | $49.13M | $31.67M |
| Current liabilities | $18.94M | $24.12M |
| Total liabilities | $18.94M | $24.24M |
| Shareholders' equity | $30.20M | $7.43M |
| Shares outstanding | 22.11M | 11.38M |
| Cash flow statement | ||
| Operating cash flow | -$31.32M | -$28.57M |
| Capital expenditure | $24,000 | $72,000 |
| Free cash flow | -$31.34M | -$28.65M |
| Investing cash flow | -$12.10M | -$72,000 |
| Financing cash flow | $46.47M | $45.09M |
| Depreciation & amortization | $34,000 | $22,000 |
| Stock-based compensation | $2.64M | $2.35M |
| Dividends paid | — | $1.09M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.